2011 Volume 73 Issue 5 Pages 482-485
A 75-year-old female had been treated with Nu-Lotan® (losartanpotassium) for hypertension. One month later, her treatment was changed from Nu-Lotan® to Preminent® (losartanpotassium/hydrochlorothiazide) and she developed pruritic edematous erythema on sun-exposed areas. Three month later eruptions appeared and pigmentations and depigmentations developed on the same areas. The minimal erythema dose (MED) of UVA was decreased to 4.4 J/cm2. On withdrawal of the Preminent®, the MED was normalized. We made a diagnosis of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®.